|
|
|
| Company |
Code |
Released |
Type |
Headline |
| ICP Biotechnology Limited |
BIO |
5 Oct, 2007, 11:30 |
PLACE |
ICPBio Places Further Shares and Warrants |
| Full Text of Announcement |
ICPBio Places Further Shares and Warrants
Auckland, New Zealand, 5 October, 2007 - New Zealand
based protein biologics manufacturing company ICP
Biotechnology Limited (NZX:BIO) today announced that
DEC International NZ Limited and BIO have agreed to
convert a loan of NZD 550,000 to equity. BIO has
consequently issued 11,000,000 ordinary shares at 5
cts to DEC as per the resolution passed at last
Friday's special general meeting to issue ordinary
shares to creditors of the company.
Today's issue follows yesterday's placement of
22,988,505 ordinary shares to DEC following its
request to convert its remaining NZD 1,200,000 of
convertible notes.
Furthermore, BIO has today allotted and issued
10,464,000 ordinary shares, 5,232,000 Series 1
Warrants and 5,232,000 Series 2 Warrants from the
Shortfall under its recent Rights Issue.
Since the Rights Issue closed, BIO has raised $965,000
cash through placing 19.34 Million ordinary shares,
9.67 Million as Series 1 Warrants and 9.67 Million
Series 2 Warrants from the Shortfall.
The Chairman, Roger Gower said today "The company
is pleased with its progress to restructure the
balance sheet and with the level of interest in the
placement of the Shortfall to date. We do expect to
make further placements".
About ICPbio Ltd
ICPbio (NZX: BIO) manufactures and markets products
for use in biopharmaceutical manufacturing,
diagnostics and animal reproduction to North America,
Europe, Australasia and South America. ICPbio Ltd is
one of New Zealand's longest established biotechnology
companies with two manufacturing facilities and core
technologies in large scale purification of proteins
and in production of sterile products. Next to its
veterinary embryo transfer product range, ICPbio's
state of the art chromatographic technology yields
high quality plasma protein products such as Albumin,
Transferrin, Immunoglobulin and Thrombin. To grow this
plasma protein business, ICPbio takes advantage of the
disease free status of New Zealand and its competitive
separation technology. The company employs
approximately 80 people. For more information, please
visit www.icpbio.com
For Further Information Please Contact:
Mr Roger Gower
Chairman, ICPBiotechnology Ltd
Tel: (09) 838 4205 |
|
| Company |
Code |
Released |
Type |
Headline |
| ICP Biotechnology Limited |
BIO |
5 Oct, 2007, 10:56 |
ALLOT |
Allotment Notice |
| Full Text of Announcement |
ISSUE OF SECURITIES BY ICP BIOTECHNOLOGY LIMITED
(BIO)
BIO advises that it has issued new shares as follows:
Class of Security: Ordinary Shares (BIO)
ISIN: NZAPHE0002S6
Number issued: 11,000,000 ordinary shares
Nominal Value: Not applicable
Issue Price: NZ$0.05
Payment: Conversion of debt owed by the Company.
Percentage of total Class
of Securities issued: 2.7% (of the total number of
ordinary shares on issue post completion of the issue)
Reason for the issue: Part satisfaction of amounts
owed by the Company.
Authority of issue: Shareholders Resolution dated 28
September 2007 and Directors' Resolution dated 4
October 2007.
Terms of issue: The new shares are credited as fully
paid, and rank in all respects equally with the shares
already on issue.
Total number of securities
of the Class in existence
after the issue: 410,618,574
Date of issue: 5 October 2007
ICP BIOTECHNOLOGY LIMITED
Susanna Stoddart
On behalf of ICP Biotechnology Limited
|
| Company |
Code |
Released |
Type |
Headline |
| ICP Biotechnology Limited |
BIO |
5 Oct, 2007, 11:11 |
ALLOT |
Allotment of Securities |
| Full Text of Announcement |
5 October 2007
NZX
Wellington
For the purposes of Listing Rule 7.12.1, BIO advises
that it has issued new shares as follows:
Class of Security: Ordinary Shares (BIO)
ISIN: NZAPHE0002S6
Number issued: 10,464,000
Nominal value: Not applicable
Issue price: NZ$0.05 each
Payment: (1) Conversion of debt owed by the Company to
a creditor in respect of 1,464,000 shares;
(2) Cash in respect of the remaining shares
Amount paid up: 100%
Percentage of total Class
of Securities issued: 2.5% (of the total number of
ordinary shares on issue post- completion of the
issue).
Reason for the issue: Placement of part of the
shortfall under the rights issue pursuant to NZSX
Listing Rule 7.3.4(c).
Authority for issue: Directors' Resolution dated 4
October 2007.
Terms of issue: The new shares are credited as fully
paid, and rank in all respects equally with the
ordinary shares already on issue.
Total number of securities
of the Class in existence
after the issue: 421,082,574
Treasury stock: Not applicable
Date of issue: 5 October 2007
ICP BIOTECHNOLOGY LIMITED
Susanna Stoddart
On behalf of ICP Biotechnology Limited |
|
|
|
|
